Semaglutide patent protection lapses in Canada
Canada's core semaglutide patent has lapsed, opening the door to generic Ozempic there — but US patents run years longer, and Canadian product cannot legally be imported.
Canada became the first G7 country to lose core patent protection for semaglutide, the active ingredient in Ozempic, Wegovy and Rybelsus, on January 4, 2026 [1]. Generic drugmakers moved quickly, with filings reported from Sandoz, Apotex, Teva and Aspen [1]. That does not mean cheaper semaglutide is on Canadian pharmacy shelves yet — regulatory clearance is a separate step, and the sources available do not confirm that any generic semaglutide had been approved in Canada as of the lapse date.
The Canadian situation is unusual. According to intellectual property analysts at Reddie & Grose, Novo Nordisk's core Canadian patent was "allowed to lapse" — the firm has publicly questioned whether the lapse was deliberate or a mistake [2]. Elsewhere, the expiry follows ordinary math: the international patent application covering semaglutide was filed in early 2006, and most countries grant a 20-year term, so core patents in China, India and Brazil expire in 2026 as well [2]. One analysis puts those three expirations in March 2026 [1], while the IP firm describes them more generally as "early 2026" [2].
Why the US timeline is different
US, European and Japanese law allow patent terms to be extended to compensate for the years spent waiting on marketing approval [2]. In the US, semaglutide's original compound patent (No. 8,536,122) carries a nominal expiration of March 20, 2026, but a second patent (No. 8,129,343) was stretched by more than five years through patent term adjustment and extension, pushing protection to December 5, 2031 [1]. In Europe, Supplementary Protection Certificates push Novo Nordisk's loss of exclusivity to 2031 as well [2].
Beyond the core molecule sits what critics call a patent thicket. One analysis counts 320 US patent applications filed on semaglutide, 154 of them granted, including 91 covering formulations, 41 covering delivery devices and 45 covering methods of treatment, with the latest potentially extending to 2042 [1]. Projected Novo Nordisk revenue during the US extension window from 2026 to 2031 has been estimated at $166 billion [1].
Secondary patents matter outside the US too. Reddie & Grose notes that generics entering Canada, China, India and Brazil this year may still run into formulation, dosing-regimen and indication patents, and that Novo Nordisk has enforced aggressively — obtaining 26 preliminary injunctions in Europe in October on a single patent [2]. Generic firms may respond with "skinny labels" that seek approval only for non-patented uses, or by trying to invalidate secondary patents in court [2]. European Patent Office appeal boards revoked three semaglutide-related patents in late 2024, while two others were upheld at first instance [2].
Why it matters for patients
For US patients, the immediate practical effect is close to zero. Generic semaglutide launching in Canada, India, China and Brazil in 2026 is not legally importable to the US [1]. The earliest realistic US generic semaglutide entry in this analysis is 2031–2032 [1]. Generic oral semaglutide is further out; the SNAC absorption technology used in Rybelsus is protected by a patent running to 2039, putting generic oral versions in the mid-2030s [1]. Generic tirzepatide (Mounjaro, Zepbound) is projected for 2036 at the earliest, with follow-on patents potentially reaching 2041 [1].
What is available now in the US is generic liraglutide, approved for Teva in August 2025, which launched at roughly $1,165 a month versus $1,300–$1,800 for brand Saxenda [1]. Liraglutide produces about 5.8% placebo-adjusted weight loss, compared with about 13.9% for semaglutide 2.4 mg and about 17.8% for tirzepatide 15 mg [1]. Cheaper does not mean equivalent.
What happens next
March 20, 2026 is the nominal expiration of semaglutide's original US compound patent, with core patents in India, China and Brazil expiring around the same time [1][2]. Patent challenges against tirzepatide become eligible May 13, 2026 [1]. Whether Canadian regulators clear any generic semaglutide, and how quickly, is not addressed in these sources.
Sources
Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.